{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T22:55:06Z","timestamp":1648853706291},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40119-015-0041-3","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T03:09:38Z","timestamp":1434942578000},"page":"131-153","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden"],"prefix":"10.1007","volume":"4","author":[{"given":"Najida","family":"Begum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Schoeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anina","family":"Fraschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bodo","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Briere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freek W. A.","family":"Verheugt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben A.","family":"van Hout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,23]]},"reference":[{"key":"41_CR1","unstructured":"World Health Organization. The top 10 causes of death 2000 and 2012. http:\/\/www.who.int\/mediacentre\/factsheets\/fs310\/en\/ . Accessed Apr 30, 2015."},{"key":"41_CR2","unstructured":"WHO. The Global Burden of Disease 2004 Update. Geneva: World Health Organization; 2008. http:\/\/www.who.int\/healthinfo\/global_burden_disease\/GBD_report_2004update_full.pdf?ua=1 . Accessed Apr 30, 2015."},{"key":"41_CR3","unstructured":"Jernberg T, Held C, Rydberg E, et al. SWEDEHEART Annual report 2014. Stockholm: Tomas Jernberg, Karolinska University Hospital; 2014. http:\/\/www.ucr.uu.se\/swedeheart\/index.php\/dokument-sh\/arsrapporter . Accessed Apr 30, 2015."},{"issue":"5","key":"41_CR4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1403494810365109","volume":"38","author":"M Rosvall","year":"2010","unstructured":"Rosvall M, Ohlsson H, Hansen O, Chaix B, Merlo J. Auditing patient registration in the Swedish quality register for acute coronary syndrome. Scand J Public Health. 2010;38(5):533\u201340.","journal-title":"Scand J Public Health."},{"key":"41_CR5","volume-title":"The ESC textbook of cardiovascular medicine","author":"CW Hamm","year":"2009","unstructured":"Hamm CW, M\u00f6llmann H, Bassand J-P, van de Werf F. Acute coronary syndromes. In: Camm AJ, L\u00fcscher TF, Serruys PW, editors. The ESC textbook of cardiovascular medicine. 2nd ed. Oxford: Oxford University Press; 2009.","edition":"2"},{"issue":"10","key":"41_CR6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4065\/84.10.917","volume":"84","author":"A Kumar","year":"2009","unstructured":"Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009;84(10):917\u201338.","journal-title":"Mayo Clin Proc"},{"issue":"23","key":"41_CR7","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"CW Hamm","year":"2011","unstructured":"Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology. Eur Heart J. 2011;32(23):2999\u20133054.","journal-title":"Eur Heart J"},{"issue":"20","key":"41_CR8","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569\u2013619.","journal-title":"Eur Heart J"},{"issue":"22","key":"41_CR9","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","volume":"31","author":"KA Fox","year":"2010","unstructured":"Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010;31(22):2755\u201364.","journal-title":"Eur Heart J"},{"key":"41_CR10","unstructured":"Bayer Pharma AG Thrombosis Advisor: A venous and arterial thrombosis resource for physicians. http:\/\/www.thrombosisadviser.com\/en\/acs\/investigational-strategies\/ . Accessed Apr 30, 2015."},{"issue":"1","key":"41_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319.","journal-title":"N Engl J Med"},{"key":"41_CR12","unstructured":"Centre for Reviews and Dissemination. CRD\u2019s guidance for undertaking reviews in health care. York: CRD; 2008. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf . Accessed Apr 30, 2015."},{"key":"41_CR13","unstructured":"National Institute for Health and Care Excellence. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. London: NICE; 2015. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag316\/documents . Accessed Apr 30, 2015."},{"key":"41_CR14","unstructured":"Bagust A, Boland A, Blundell M, et al. Liverpool Reviews and Implementation Group (LRiG). Ticagrelor for the treatment of acute coronary syndromes. Liverpool: The University of Liverpool; 2011. http:\/\/www.nice.org.uk\/guidance\/ta236\/documents\/acute-coronary-syndromes-ticagrelor-evidence-review-group-report2 . Accessed Apr 30, 2015."},{"issue":"4","key":"41_CR15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jval.2010.11.012","volume":"14","author":"DJ Crespin","year":"2011","unstructured":"Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health. 2011;14(4):483\u201391.","journal-title":"Value Health."},{"issue":"10","key":"41_CR16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00019053-200624100-00009","volume":"24","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24(10):1021\u201333.","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"41_CR17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1524-4733.2008.00338.x","volume":"11","author":"J Latour-P\u00e9rez","year":"2008","unstructured":"Latour-P\u00e9rez J, de Miguel Balsa E, Beteg\u00f3n L, Badia X. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. Value Health. 2008;11(5):853\u201361.","journal-title":"Value Health."},{"issue":"11","key":"41_CR18","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"20","key":"41_CR19","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"41_CR20","first-page":"992","volume":"35","author":"JL Mega","year":"2014","unstructured":"Mega JL, Braunwald E, Murphy S, et al. Rivaroxaban in patients after an acute coronary syndrome with cardiac biomarker elevation: insights from the ATLAS ACS 2-TIMI 51 Trial. Eur Heart J. 2014;35(Suppl 1):992.","journal-title":"Eur Heart J"},{"issue":"12","key":"41_CR21","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2165\/00019053-200725120-00007","volume":"25","author":"B Heeg","year":"2007","unstructured":"Heeg B, Damen J, van Hout B. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer\u2019s perspective. Pharmacoeconomics. 2007;25(12):1063\u201382.","journal-title":"Pharmacoeconomics."},{"key":"41_CR22","unstructured":"Pharmaceutical Benefits Board Sweden. Changes to the general guidelines for economic evaluations from the Pharmaceutical Benefits Board LFNAR 2003:2 (TLVAR 2015:1); 2015. http:\/\/www.tlv.se\/Upload\/Lagar_och_foreskrifter\/TLVAR_2015_1.pdf Accessed May 15, 2015."},{"key":"41_CR23","unstructured":"Statistiska centralbyr\u00e5n. Konsumentprisindex (1980\u00a0=\u00a0100), fastst\u00e4llda tal. http:\/\/www.scb.se\/sv_\/Hitta-statistik\/Statistik-efter-amne\/Priser-och-konsumtion\/Konsumentprisindex\/Konsumentprisindex-KPI\/33772\/33779\/Konsumentprisindex-KPI\/272151\/ . Accessed Nov 22, 2013."},{"key":"41_CR24","unstructured":"Ekman M. Consumption and production age in Sweden: basic facts and health economic implications. Dissertation for the degree of Doctor of Philosophy at the Stockholm School of Economics; 2002."},{"key":"41_CR25","unstructured":"F\u00f6rs\u00e4kringskassan. Beslutsst\u00f6det: Sjukskrivningsm\u00f6nster f\u00f6re och efter inf\u00f6randet av f\u00f6rs\u00e4kringsmedicinska rekommendationer f\u00f6r fysiska sjukdomar. Socialf\u00f6rs\u00e4kringsrapport 2009;5. https:\/\/www.forsakringskassan.se\/wps\/wcm\/connect\/6043de6a-abf1-44ac-a48d-a92eb438a50d\/socialforsakringsrapport_2009_5.pdf?MOD=AJPERES . Accessed Apr 30, 2015."},{"key":"41_CR26","unstructured":"Skatteverket. Arbetsgivaravgifternas sammans\u00e4ttning; 2011. http:\/\/www.skatteverket.se\/foretagorganisationer\/arbetsgivare\/socialavgifter\/arbetsgivaravgifter.4.233f91f71260075abe8800020817.html . Accessed Nov 22, 2013."},{"key":"41_CR27","unstructured":"Statistiska centralbyr\u00e5n. Genomsnittlig m\u00e5nadsl\u00f6n efter sektor 1992\u20132011: Samtliga sektorer: 2011. http:\/\/www.scb.se\/sv_\/Hitta-statistik\/Statistik-efter-amne\/Arbetsmarknad\/Loner-och-arbetskostnader\/Lonestrukturstatistik-hela-ekonomin\/14367\/14374\/149087\/ . Accessed Nov 22, 2013."},{"key":"41_CR28","unstructured":"European Central Bank. Eurosystem. Euro foreign exchange reference rates. http:\/\/www.ecb.europa.eu\/stats\/exchange\/eurofxref\/html\/eurofxref-graph-sek.en.html . Accessed Jan 3, 2014."},{"issue":"7","key":"41_CR29","first-page":"494","volume":"385","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;385(7):494\u2013502.","journal-title":"N Engl J Med"},{"key":"41_CR30","unstructured":"Socialstyrelsen. Statistikdatabas f\u00f6r diagnoser i sluten v\u00e5rd. http:\/\/www.socialstyrelsen.se\/statistik\/statistikdatabas\/diagnoserislutenvard . Accessed Nov 22, 2013."},{"key":"41_CR31","unstructured":"Official Statistics of Sweden. Life tables for 2010, divided into men and women. http:\/\/www.scb.se\/Statistik\/BE\/BE0101\/2013A02F\/Be0101Livsl%C3%A4ngdstabeller_13_eng.xls . Accessed Nov 14, 2013."},{"issue":"23","key":"41_CR32","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","volume":"29","author":"F Werf van de","year":"2008","unstructured":"van de Werf F, Bax J, Betriu A, et al. ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29(23):2909\u201345.","journal-title":"Eur Heart J"},{"issue":"4","key":"41_CR33","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCOUTCOMES.111.964700","volume":"5","author":"K Smolina","year":"2012","unstructured":"Smolina K, Wright FL, Rayner M, Goldacre MJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5(4):532\u201340.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"41_CR34","unstructured":"Socialstyrelsen. D\u00f6dsorsaksstatistik. http:\/\/www.socialstyrelsen.se\/statistik\/statistikefteramne\/dodsorsaker . Accessed Nov 14, 2013."},{"key":"41_CR35","doi-asserted-by":"crossref","unstructured":"Isaksson R, Jansson J, Lundblad D, et al. Better long-term survival in young and middle aged women than in men after a first myocardial infarction between 1985 and 2006. An analysis of 8,630 patients in the Northern Sweden MONICA study. BMC Cardiovasc Disord 2011;11(1):1\u20138.","DOI":"10.1186\/1471-2261-11-1"},{"issue":"2","key":"41_CR36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/1741826710389368","volume":"18","author":"B Sigvant","year":"2011","unstructured":"Sigvant B, Henriksson M, Lundin F, Wahlberg E. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective? Eur J Cardiovasc Prev Rehabil. 2011;18(2):254\u201361.","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"41_CR37","volume-title":"Kostnader f\u00f6r insjuknande i stroke \u00e5r 2009. En incidensbaserad studie","author":"O Ghatnekar","year":"2012","unstructured":"Ghatnekar O, Steen Carlsson K. Kostnader f\u00f6r insjuknande i stroke \u00e5r 2009. En incidensbaserad studie. Lund: IHE; 2012."},{"key":"41_CR38","unstructured":"Socialstyrelsen. Nationella vikter f\u00f6r slutenv\u00e5rdsgrupper, NordDRG CC-versionen 2013. http:\/\/www.socialstyrelsen.se\/klassificeringochkoder\/norddrg\/vikter . Accessed Nov 22, 2013."},{"key":"41_CR39","unstructured":"TLV. L\u00e4kemedel. http:\/\/www.tlv.se\/beslut\/sok\/lakemedel\/ . Accessed Feb 13, 2013."},{"key":"41_CR40","unstructured":"Olofsson G. Age, work and retirement in Sweden\u2014views, policies and strategies of key actors: an overview of work pensions and early exit as well as state policies and employer strategies towards the older workforce. Background paper on the Swedish case for the \u2018Millennium Project\u2019 conference in Tokyo. Tokyo: Japanese Institute of Labour; 2001."},{"key":"41_CR41","unstructured":"Socialstyrelsen. Statistikdatabasen f\u00f6r diagnoser i sluten v\u00e5rd. http:\/\/192.137.163.49\/sdb\/par\/val.aspx . Accessed Oct 25, 2012."},{"issue":"5","key":"41_CR42","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318.","journal-title":"Value Health."}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-015-0041-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T10:14:13Z","timestamp":1498212853000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40119-015-0041-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,23]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["41"],"URL":"https:\/\/doi.org\/10.1007\/s40119-015-0041-3","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,23]]}}}